Request Free Sample ×
United States Contract Research Organization Service Market Research Report —Forecast till 2035 Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Contract Research Organization Market

ID: MRFR/HC/11454-HCR
128 Pages
Satyendra Maurya
Last Updated: April 24, 2026
United States Contract Research Organization Service Market Research Report: Size, Share, Trend Analysis By Types (Clinical Research Services, (Phase, [Phase III, Phase II, Phase I, Phase IV], and Study Design (For Phase III & IV), [Interventional, Real World Evidence (RWE)]), Early phase development Services, [Chemistry, Manufacturing and Controls Services, Preclinical Services, and Discovery Studies], Laboratory Services, [Analytical Testing Services, Bioanalytical Testing Services], Consulting Services, and Data Management Services), By Therapeutic Area (Oncology (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Other Cancer), Infectious Diseases, CNS Disorders, Neurology, Vaccines, Metabolic Disorders/Endocrinology, Immunological Disorders, Psychiatry, Respiratory Disorders, Dermatology, Ophthalmology, Gastrointestinal Diseases, Genitourinary & Women’s Health, Haematology, and Other Therapeutic Areas), By End Users (Pharmaceutical & Biopharmaceutical Companies, Medical Device Companies, and Academic Institutes) - Growth Outlook & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Contract Research Organization Market Infographic
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Pharmaceutical, BY Service Type (USD Billion)
      1. 4.1.1 Clinical Research Services
      2. 4.1.2 Preclinical Services
      3. 4.1.3 Laboratory Services
      4. 4.1.4 Consulting Services
    2. 4.2 Pharmaceutical, BY Therapeutic Area (USD Billion)
      1. 4.2.1 Oncology
      2. 4.2.2 Cardiology
      3. 4.2.3 Neurology
      4. 4.2.4 Infectious Diseases
      5. 4.2.5 Endocrinology
    3. 4.3 Pharmaceutical, BY End User (USD Billion)
      1. 4.3.1 Pharmaceutical Companies
      2. 4.3.2 Biotechnology Companies
      3. 4.3.3 Medical Device Companies
      4. 4.3.4 Academic Institutions
    4. 4.4 Pharmaceutical, BY Phase of Development (USD Billion)
      1. 4.4.1 Preclinical
      2. 4.4.2 Phase I
      3. 4.4.3 Phase II
      4. 4.4.4 Phase III
      5. 4.4.5 Phase IV
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Pharmaceutical
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 IQVIA (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Labcorp Drug Development (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 PPD (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Charles River Laboratories (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Syneos Health (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Medpace (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 PRA Health Sciences (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Wuxi AppTec (CN)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Eurofins Scientific (LU)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY SERVICE TYPE
    3. 6.3 US MARKET ANALYSIS BY THERAPEUTIC AREA
    4. 6.4 US MARKET ANALYSIS BY END USER
    5. 6.5 US MARKET ANALYSIS BY PHASE OF DEVELOPMENT
    6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
    9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
    11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
    12. 6.12 PHARMACEUTICAL, BY SERVICE TYPE, 2024 (% SHARE)
    13. 6.13 PHARMACEUTICAL, BY SERVICE TYPE, 2024 TO 2035 (USD Billion)
    14. 6.14 PHARMACEUTICAL, BY THERAPEUTIC AREA, 2024 (% SHARE)
    15. 6.15 PHARMACEUTICAL, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion)
    16. 6.16 PHARMACEUTICAL, BY END USER, 2024 (% SHARE)
    17. 6.17 PHARMACEUTICAL, BY END USER, 2024 TO 2035 (USD Billion)
    18. 6.18 PHARMACEUTICAL, BY PHASE OF DEVELOPMENT, 2024 (% SHARE)
    19. 6.19 PHARMACEUTICAL, BY PHASE OF DEVELOPMENT, 2024 TO 2035 (USD Billion)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY SERVICE TYPE, 2025-2035 (USD Billion)
      2. 7.2.2 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
      3. 7.2.3 BY END USER, 2025-2035 (USD Billion)
      4. 7.2.4 BY PHASE OF DEVELOPMENT, 2025-2035 (USD Billion)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Pharmaceutical Market Segmentation

Pharmaceutical By Service Type (USD Billion, 2025-2035)

  • Clinical Research Services
  • Preclinical Services
  • Laboratory Services
  • Consulting Services

Pharmaceutical By Therapeutic Area (USD Billion, 2025-2035)

  • Oncology
  • Cardiology
  • Neurology
  • Infectious Diseases
  • Endocrinology

Pharmaceutical By End User (USD Billion, 2025-2035)

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Medical Device Companies
  • Academic Institutions

Pharmaceutical By Phase of Development (USD Billion, 2025-2035)

  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035